ArticleEuropean urology focus2019
The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Article in European urology focus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.British journal of cancer · 2021Trial
- Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.European urology · 2026Review
- Rapidly Progressive Retroperitoneal Dissemination of Plasmacytoid Urothelial Carcinoma Presenting With Multiorgan Obstruction After Radical Cystectomy: A Case Report.IJU case reports · 2026Article
- Plasmacytoid urothelial carcinoma of the urinary bladder with colorectal metastasis and mimicking colitis: A case report.World journal of clinical cases · 2025Article
- Acute renal failure in the setting of bilateral ureteral obstruction secondary to plasmacytoid variant urothelial cell carcinoma.Urology case reports · 2025Article
- Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma.Frontiers in oncology · 2025Article
- Article
- Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.Urologic oncology · 2024Review
- Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.Human pathology · 2024Article
- One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.Current treatment options in oncology · 2024Review
- Metastatic Plasmacytoid Urothelial Carcinoma Masquerading as a Primary Signet Ring Cell Carcinoma of the Duodenum.Cureus · 2023Article
- The Many Faces of Urothelial Carcinomas: An Update From Pathology to Clinical Approach and Challenges in Practice.Urology research & practice · 2023Article
- Article
- Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter?International urology and nephrology · 2022Article
- Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma.The Journal of urology · 2022Article
- Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis.IJU case reports · 2022Article
- Clinically undetected plasmacytoid urothelial carcinoma of the urinary bladder with non-mass-forming metastases in multiple organs: an autopsy case.Journal of pathology and translational medicine · 2022Article
- Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients.World journal of urology · 2022Article
- Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes.Translational andrology and urology · 2022Review
- T1 bladder carcinoma with variant histology: pathological features and clinical significance.Virchows Archiv : an international journal of pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe clinical significance of the plasmacytoid variant (PCV) in urothelial carcinoma (UC) is currently lacking.
objectiveTo compare clinical outcomes of patients with any PCV with that of patients with pure UC treated with radical cystectomy (RC). DESIGN, SETTING, AND
participantsWe identified 98 patients who had pathologically confirmed PCV UC and 1312 patients with pure UC and no variant history who underwent RC at our institution between 1995 and 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox regression and Cox proportional hazards regression to determine if PCV was associated with overall survival (OS). RESULTS AND LIMITATIONS: Patients with PCV UC were more likely to have advanced tumor stage (p=0.001), positive lymph nodes (p=0.038), and receive neoadjuvant chemotherapy than those with pure UC (46% vs 22%, p<0.0001). The rate of positive soft tissue surgical margins was over five times greater in the PCV UC group compared with the pure UC group (21% vs 4.1%, respectively, p<0.0001). Median OS for the pure UC versus the PCV patients were 8 yr and 3.8 yr, respectively. On univariable analysis, PCV was associated with an increased risk of overall mortality (hazard ratio=1.34, 95% confidence interval: 1.02-1.78, p=0.039). However, on multivariable analysis adjusted for age, sex, neoadjuvant chemotherapy received, lymph node status, pathologic stage, and soft margin status, the association between PCV and OS was no longer significant (hazard ratio=1.06, 95% confidence interval: 0.78, 1.43, p=0.7). This retrospective study is limited by the lack of pathological reanalysis, and the impact of other concurrent mixed histology cannot be determined in this study.
conclusionsPatients with PCV features have a higher disease burden at RC compared with those with pure UC. However, PCV was not an independent predictor of survival after RC on multivariable analysis, suggesting that PCV histology should not be used as an independent prognostic factor. PATIENT SUMMARY: Plasmacytoid urothelial carcinoma is a rare and aggressive form of bladder cancer. Patients with plasmacytoid urothelial carcinoma had worse adverse pathologic features, but this was not associated with worse overall mortality when compared with patients with pure urothelial carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.